Opternative Sues Warby Parker Over Online Eye Exams

November 10, 2017: By Jon Swedien

legal issuesOpternative, the Chicago-based online vision test company, has filed a lawsuit against online eyewear retailer Warby Parker. The suit follows Warby Parker’s launch of a competing online vision test.

In the suit, filed Oct. 16, Opternative said Warby Parker breached nondisclosure agreements and misappropriated trade secrets when it launched its online eye exam in May 2017. Opternative launched its online eye exam in 2015.

In 2013, when Opternative was still developing its test, the company had discussions with Warby Parker about a potential partnership and possibly an acquisition by Warby Parker of Opternative.

During those discussions, Opternative said it required Warby Parker to sign nondisclosure agreements as it shared proprietary information. Opternative alleges Warby Parker violated those agreements in creating an online eye exam that is derivative of its own.

No partnership or acquisition was ever agreed to among the companies.

“Despite assurances to the contrary, Warby Parker had already developed an intent to develop its own online eye exam system, even as it negotiated for unfettered access to the inner workings of Opternative’s system,” the suit states.

Warby Parker has filed a motion to dismiss the lawsuit. In its motion to dismiss, Warby Parker said Opternative’s suit fails to show similarities between the two eye exams and the information Opternative shared was “limited, nontechnical information.”

“This action is an attempt by the plaintiff to recover through the courts where it has failed in the marketplace,” Warby Parker said in the motion.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023